Key result
Adding ezetimibe to statins lowers LDL-C ~13% more than doubling the statin dose.
RCT (n=885)
Open-label
Yes
Answers are grounded in this paper and cite their sources.
INTRODUCTION: When a standard dose of statins fails to achieve lipid control in patients at high risk for coronary artery disease (CAD), increasing the statin dosage or co-administration of additional agents is recommended. The aim of this study was to compare the safety and lipid-lowering efficacy of doubling the standard statin dose (STAT2) to that of co-administering ezetimibe 10 mg/day (EZE+statin) in Canadian patients at high CAD risk with persistent hyperlipidemia upon statin treatment. MATERIAL AND METHODS: Six-week, open-label, randomized, multicentre study. The primary outcome was the change in plasma LDL-C and secondary measures included the change in additional lipid parameters. Safety was assessed with the incidence of emergent adverse events (AEs). RESULTS: Eight hundred eighty-five patients (EZE+statin, n=586; STAT2, n=299) completed the study. The mean (SD) percent change in low-density lipoprotein cholesterol (LDL-C) was - 30.9% (18.2) for the EZE+statin group and -18.4% (19.0) for the STAT2 group (p=0.001). Percent and absolute decreases in total cholesterol (TC), triglycerides and the TC to high-density lipoprotein cholesterol ratio (TC/HDL-C) were significantly greater for the EZE+statin group (p = 0.001). After 6 weeks of treatment, 70% of the patients in the EZE+statin group and 48% of patients in the STAT2 group (OR=2.45, p<0.001) achieved target LDL-C levels of<2.5 mmol/l. Incidence of AEs was similar between groups, with the exception of a higher incidence of muscle disorders in the STAT2 group. CONCLUSIONS: In patients at high CAD risk who are above the LDL-C target while on statin monotherapy, co-administration of ezetimibe is well tolerated and more effective in improving the lipid profile compared to doubling the existing statin dose.
No takes yet. Share an insight, caveat, or question.
Pandey et al. (2011) conducted an RCT in Persistent hyperlipidemia (n=885). Ezetimibe co-administered with statins vs. Doubling the standard statin dose was evaluated on Change in plasma LDL-C (p=0.001). Co-administration of ezetimibe with statins reduced plasma LDL-C more effectively than doubling the statin dose in high-risk patients with hyperlipidemia.
Synapse has enriched 10 related papers. Consider them for comparative context: